Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • BI 655066 - Psoriasis
    Clinical Study Number 1311.2
    Study Indication Psoriasis
    Product BI 655066
    Generic Name BI 655066
    Lab Code
    Clinical Phase II
    Study Title

    A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-controlled (ustekinumab), double-blind within dose groups of BI 655066)

    Study Document
    Trial synopsis 1311.2_DR english